Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Discover how President Trump's Most Favored Nation policy aims to slash U.S. prescription drug prices by up to 1500% and its potential political impact.

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

VANCOUVER, British Columbia and KIBBUTZ YIFAT, Israel, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE:BOIL) (OTCQB:BEOLF) ('Beyond Oil” or the 'Company”), a food-tech innovation company ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...

HOUSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (Nasdaq: FRGT; "Fr8Tech” or the "Company”), a logistics ...